Enhertu–trastuzumab deruxtecan, which it is jointly developing and commercializing with Daiichi Sankyo–had met prespecified criteria for objective response rate and duration of response.
You are here: Home / Top Stories / Dow Jones Newswires: AstraZeneca says cancer drug Enhertu showed positive results